

Investor Newsletter

Issue 02 2015



MicroPort Attends J.P. Morgan Healthcare Conference

From January 12 to January 15, the 33rd Annual J.P. Morgan Healthcare Conference was held in San Francisco of the US. Shanghai MicroPort Medical (Group) Co (“MicroPort”) attended the conference. We introduced the company’s recent development and future plan, and had group discussions with several investment bank analysts.



MicroPort Holds Coronary Heart Disease Lecture in Lanzhou

On January 21, in partnership with Lanzhou PetroChemical Hospital, MicroPort held a lecture on coronary heart disease in Lanzhou, Gansu Province, and around 100 people were attracted to attend the training. Doctors of Lanzhou PetroChemical Hospital educated the attendees about coronary heart diseases to help relieve their fear for coronary heart disease surgery. In the lecture, participants learnt about causes and symptoms of coronary heart disease, how lifestyle changes can prevent heart diseases and how a stent is implanted into the heart. Doctors also offered free consultancy services to coronary heart disease patients.




MicroPort Attends Asia PCR/Singapore LIVE Conference

From January 22 to January 24, MicroPort attended 2015 Asia PCR/Singapore LIVE conference that was held in Singapore. The conference attracts around 2,000 healthcare professionals from more than 70 countries including Singapore, India, Indonesia, Malaysia and Thailand annually. During the conference, we rebroadcasted two surgeries in which Firehawk® was used to treat left main bifurcation lesions to prove its safety and efficacy, which was well received by people in attendance.

MicroPort Promotes Firehawk® in Clinical Cardiovascular Conference

From January 29 to February 1, the sixth Clinical Cardiovascular Conference was held in Beijing. MicroPort attended and hosted a satellite meeting to promote our star product Firehawk®. We invited several cardiovascular specialists to deliver speeches on Firehawk®'s special features and TARGET products' latest clinical outcome.



PTCA Balloon Inflation Catheter Selected as National Key New Product

On February 13, PTCA Balloon Inflation Catheter ($\Phi 1.5 \sim 4.0$ mm) was selected as one product under the “2014 National Key New Product Scheme,” a program launched by the Ministry of Science and Technology since 1988 to support the development of domestic innovative products. It is the sixth time for MicroPort to receive such an honor.



MicroPort EP Launches Community Activity

On February 12, Shanghai MicroPort EP MedTech Co (“MicroPort EP”) launched a community activity to evaluate local elders’ physical fitness with its self-developed ECG device.

MicroPort Gains CFDA Registration Certificate for Orthopedic Product

On January 29, MicroPort gained a China Food and Drug Administration (“CFDA”) registration certificate for Evolution MP Adaptive CS&PS Insert which is used in total knee arthroplasty, valid from January 16, 2015 to January 15, 2020.



Angiographic Catheter Awarded Registration Certificate

Shanghai MicroPort Access Medtech Co (“MicroPort Access”), a subsidiary of MicroPort, recently gained a registration certificate for its Angiographic Catheter from CFDA. This Angiographic Catheter includes six additional distal end configurations, such as coronary artery LRS, RH and Cobra.

MicroPort Access Angiographic Catheter is used for coronary artery angiography and peripheral vascular angiography. Its distal tip is designed with innovative “Full-radius” structure. Its extra soft material can reduce the damage of blood vessel and provide better cross ability. With six distal end configurations, the Angiographic Catheter offers more options for surgeons and is expected to increase its market share in the future.

Evolution™ Launched in Hong Kong



Shanghai MicroPort Orthopedics Co ("MicroPort Orthopedics Shanghai") recently announced that its second generation medial-pivot Evolution™ Medial-Pivot Knee System was officially launched in Hong Kong.

The Evolution™ builds on over 16 years of excellent clinical history of the Advance® Medial-Pivot Knee System which was launched in 1998. Up to date, more than 96,000 Advance® have been implanted worldwide. Peer-reviewed literature has shown the Advance® to be more stable and patient-preferred compared to traditional total knee implants.

Compared to the Advance®, the Evolution™ includes advancements in implant function and fit. It is differentiated through anatomic features that reproduce natural movement and stability, resulting in function more like a normal healthy knee. To offer better implant fit for patients, the Evolution™ features an expanded number of implant sizes and the anatomic tibial base.


"The Evolution™ is designed to replicate the movement and stability of a normal, healthy knee by incorporating a patented ball-in-socket feature on the medial side. As it is designed based on the success of the Advance®, I'm very confident in the clinical result of the Evolution™," said Professor Peter KY Chiu from Department of Orthopaedics & Traumatology of the University of Hong Kong, Queen Mary Hospital.

"The Evolution™ features high flexion stability, low bone cut and low wear. For surgeons, it's an important system for clinical study of total knee replacement. For patients, it would offer a more stable and natural feel during normal daily activities after surgery."



"The Evolution™ is the only medial-pivot knee in the world that has gained FDA's approval for market launch and we believe its launch in the Hong Kong market will reinforce the brand image and increase market share for MicroPort Orthopedics," said Simon Chen, Vice President of Marketing and Sales of MicroPort Orthopedics Shanghai. "We will continue to develop safe and high-quality products to offer innovative solutions for surgeons and patients."

MicroPort Endovascular Releases Six-month Follow-up Data of Castor



MicroPort Endovascular (Shanghai) Co (“MicroPort Endovascular”) recently released the six-month follow-up data of its in-house developed Castor Branched Aortic Stent Graft System on Vascular News, an important source for news, views, comment and controversy in the vascular industry.

Six-month data of the Castor trial from 73 patients demonstrate safety and efficacy of the branched aortic stent graft system for the treatment of thoracic dissections. Conducted at 11 centers in China, the trial met its primary efficacy endpoint by achieving 98.6% technical success with two occlusions of the left subclavian artery for operational reasons. No further branch artery occlusions were observed during six-month follow-up. The six-month stroke rate is 2/70, which was not device related. There are two device-related severe adverse events, including one endoleaks and one reintervention due to distal development of the dissection.

Castor is the world’s first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. Castor employs an easy-to-use unibody design, including a main body and a left subclavian branch graft to avoid type III endoleaks.

The clinical trial of Castor stent-graft system is the world’s first prospective, randomized, multi-center clinical study. In August 2014, Castor was listed in Shanghai Biomedical Industrialization Project 2014. In November 2014, it was selected as one project of the National Key Technology R&D Program for China's 12th Five-Year Plan.

PROFEMUR™ Classic TL Hip Stem Awarded CFDA Registration Certificate

PROFEMUR™ Classic TL Hip Stem, a hip device developed by MicroPort Orthopedics, was recently awarded registration certificate from CFDA.

PROFEMUR™ Classic TL Hip Stem is used in total hip arthroplasty, designed to cure hip pain and hip functional disabilities caused by hip diseases such as osteoarthritis, rheumatic arthritis and femoral neck fracture. The device features reduced lateral shoulder, which helps to conserve bone end and ease insertion, and plasma spray, which helps to increase initial stability and longevity.

Within each PROFEMUR™ family, MicroPort Orthopedics is investing to provide a Simply Versatile offering of hip stems, and PROFEMUR™ Classic TL Hip Stem is no exception. It shares the same instrumentation with PROFEMUR™ TL modular stem, offering surgeons more options and flexibility.

PROFEMUR™ Classic TL Hip Stem is designed based on Mueller tapered stem, which is a typical American style stem design. It and European-style PROFEMUR™ Classic Z Hip Stem form a complete product line of hip stem.

PROFEMUR™ Classic TL Hip Stem was first launched in the US in 2012 and PROFEMUR™ TL modular stem was launched in 2006.



MicroPort Orthopedics Counted Among “10 to Watch” by the Greater Memphis Chamber

MicroPort Orthopedics was recognized as one of the 10 local companies to watch in 2014, ranked at fourth, according to an announcement the Greater Memphis Chamber released on February 4. Every year, the Greater Memphis Chamber names 10 companies and organizations that stand out in the year for their leadership in the community, whether that be through driving the local economy, inspiring innovation or embracing change.

“These 10 Memphis businesses were chosen for the tremendous accomplishments they made in 2014 and the promise of what’s yet to come,” said Phil Trenary, President and CEO of the Greater Memphis Chamber. “The Chamber proudly recognizes these members for the jobs and talent they bring to Memphis, and we look forward to their future success.”

The Greater Memphis Chamber is the lead economic development organization for Memphis/Shelby County, and is a private, non-profit, membership-driven organization comprised of 2,400 business enterprises, civic organizations, educational institutions and individuals.





MicroPort Promotes Joint Products in Heilongjiang Province

On January 23, MicroPort Orthopedics Shanghai organized a meeting in Heilongjiang Provincial Hospital to promote our products. We introduced the features and advantages of our orthopedic products, mainly focused on SuperPath™ tissue-sparing surgical technique, Advance® and Evolution™ Medial-Pivot knee and Prophecy™ Pre-Operative Navigation Guides. The meeting attracted a lot of attention. It was closed with an active Q&A session which stimulated the audience and the faculty.

First Bilateral Total Hip Arthroplasty in Heilongjiang Province

On January 29, surgeons in Heilongjiang Provincial Hospital successfully completed the first bilateral total hip arthroplasty in Heilongjiang Province, using MicroPort Orthopedics PROFEMUR™ Z Hip Stem and ceramic-on-ceramic prosthesis.



PROFEMUR® Z

PROFEMUR® Z



Investor Newsletter

Issue **02** 2015



For more information, please contact:

Hongbin Sun

Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com

Xun You

Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com